To Become a Long-Term Partner
for Global Innovative Biotech Companies
Established in 2008, Viva Biotech (01873.HK) provides one-stop services ranging from early-stage structure-based drug R&D to commercial manufacturing to global biopharmaceutical innovators.
We offer leading early-stage to late-phase drug discovery expertise by integrating our dedicated team of experts, cutting-edge technology platforms, and state-of-the-art equipment in X-ray crystallization, Cryo-EM, DEL, ASMS, SPR, HDX, AIDD/CADD, and much more. Our business covers all aspects of therapeutic strategies and drug modalities, including small molecules and biologics across the pharma and biotech spectrum. The experienced chemistry team, led by senior medicinal chemists and drug discovery biologists, provides services for drug design, medicinal chemistry (hit to lead and lead optimization), custom synthesis, chemical analysis and purification, kilogram scale-up, peptide synthesis and corresponding bioassays. With our subsidiary, Langhua Pharma, we offer our worldwide pharmaceutical and biotech partners a one-stop integrated CMC (Chemical, Manufacturing, and Control) service from preclinical to commercial manufacturing. Additionally, Viva embedded an equity for service (EFS) model to high potential startups to address unmet medical needs.
-
2,465Biotech and pharmaceutical clients worldwide -
2,063Employees worldwide -
93Invested and incubated companies
cro
Drug R&D Services
With its leading position in Structure-Based Drug Discovery (SBDD), Viva provides state-of-the-art drug research and development services to global biotechnology and pharmaceutical customers for their preclinical, innovative drug discovery programs. We cover the all-around needs of our clients for their early drug research and development, including protein expression, purification and structure determination, hits screening, therapeutic antibody discovery, antibody expression and production, Bioassay, computer-aided drug design, medicinal chemistry and custom synthesis, ADME, and PK studies.
cdmo
R&D and Production Services
As the subsidiary of Viva Biotech holdings, Langhua offers our worldwide partners One-Stop CDMO solution in new drug full life-cycle for small molecule Active Pharmaceutical Ingredients (APIs) and Finished Dosage Form, from pre-clinical to commercial supply.
Learn more
One-stop services ranging from early-stage Structure-Based Drug R&D to commercial manufacturing
News
Company News
-
2025/06/06New Research Progress in Protein Structure: Viva Biotech Reveals the FANCM Helicase Domain Structure Published in the EMBO Journal
-
2025/05/28Viva Biotech Participates in the Establishment of a RMB 300 Million Venture Capital Fund, with Continued Focus on Early-Stage Biopharmaceutical Innovation
Subscribe to Our Newsletter